| Powder: | Yes |
|---|---|
| Customized: | Customized |
| Certification: | GMP, ISO 9001, USP, BP |
| Suitable for: | Elderly, Adult |
| State: | White Powder |
| Purity: | >98% |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier
What is Agomelatine?
Do you think agomelatine is a solid antidepressant? How do you think it compares to other more typical antidepressants like Prozac?
Agomelatine's unique pharmacology and favorable side effect profile make it a boon for depressed patients, especially those who have not responded to conventional antidepressants.
Application:
Valdoxan tablets contain the active ingredient agomelatine, which is a type of medicine called an antidepr
essant. It is used to treat depression.
Agomelatine acts on the melatonin and serotonin receptors in the brain.
Melatonin is a hormone made by the pineal gland, a structure in the brain. It is normally released soon after it starts to get dark. The amount produced then increases until about four am, before dropping off again. Melatonin is linked with the control of circadian rhythms and promoting sleep. It works by acting on melatonin receptors in the brain.
Agomelatine mimics the action of melatonin and helps to re-synchronise the body's circadian rhythms. These include mood, anxiety, appetite, body temperature and sleep/wake cycles. These circadian rhythms, particularly sleep cycles, are severely disturbed in people with depression. Agomelatine's main action is to improve the onset and quality of sleep and this in turn has an antidepressant effect.
Agomelatine also helps to improve mood in depression by increasing noradrenaline and dopamine release in the brain. These are natural chemicals called neurotransmitters that are involved, amongst other things, in regulating mood.
Usage:
Agomelatine is indicated for the treatment of major depressive episodes in adults.Ten placebo controlled trials have been performed to investigate the short term efficacy of agomelatine in major depressive disorder. At the end of treatment, significant efficacy was demonstrated in six of the ten short-term double-blind placebo-controlled studies.Two were considered "failed" trials, as comparators of established efficacy failed to differentiate from placebo. Efficacy was also observed in more severely depressed patients in all positive placebo-controlled studies.The maintenance of antidepressant efficacy was demonstrated in a relapse prevention study.
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}